|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
GBSI provided similar rates of atrophy, but reduced measurement variability compared to CSA in all MS subtypes (CIS: -0.95 ± 2.11% vs -1.19 ± 3.67%; RRMS: -1.74 ± 2.57% vs -1.74 ± 4.02%; PMS: -2.29 ± 2.40% vs -1.29 ± 3.20%) and healthy controls (0.02 ± 2.39% vs -0.56 ± 3.77%).
|
31385358 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atrophy was located between C1/C2 and C5 in patients with RRMS vs patients with CIS, and widespread along the cord in patients with progressive MS vs patients with RRMS, with an additional C5/C6 involvement in patients with SPMS vs patients with PPMS.
|
31611336 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that there is a prodromal period before CIS which is not unique to MS.
|
31319354 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All balance parameters were found more impaired in MS group compared to controls and CIS.
|
30223228 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provided imaging evidence for DTI abnormalities in CIS and MS and suggested that DTI can improve our knowledge of the path physiology of CIS and MS and clinical progression.
|
29754967 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After excluding these typical MS cases, we analyzed the remaining 29 cases of other CNS inflammatory demyelinating diseases, including atypical MS (n = 14), acute transverse myelitis, TM (n = 8), acute disseminated encephalomyelitis, ADEM (n = 3), clinically isolated syndrome, CIS (n = 2), atypical optic neuritis, ON (n = 1), and NMO (n = 1).
|
30284401 |
2018 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never.
|
28155573 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows that loss of balance among various members of the SOCS family proteins may contribute to pathophysiology of multiple sclerosis.
|
28196747 |
2017 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty-three MS patients (21 clinically isolated syndrome suggestive of MS [CIS], 15 RRMS, 7 progressive [PMS]) and 10 healthy controls (HC) were studied.
|
29045421 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Headaches were prevalent in 78% of patients in our population with newly diagnosed CIS and MS.
|
29299379 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network.
|
22245284 |
2012 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to compare sensitivity of a novel and the standard procedure with peroxidase immunodetection in a large number of CIS and MS patients.
|
22277297 |
2012 |